Medicare Part D open enrollment and what recent changes mean for beneficiaries

It’s that time of year again: Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their...
Read More
Many seniors are paying more for Part D medicines than their insurer

For seniors who rely on Medicare Part D, the out-of-pocket costs for medicines can sometimes be a barrier. Insurers and pharmacy benefit managers (PBMs) continue to shift more and more costs to...
Read More
Busting 3 Myths About Copay Coupons

Insurer-imposed barriers like high deductibles and coinsurance shift the cost of life-saving care onto patients. Manufacturers and others have stepped forward to assist patients who face high...
Read More
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease

There’s been a lot of discussion this year about the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) for new Alzheimer’s treatments finalized earlier this year in...
Read More
Myth vs. Fact: The Senate’s latest price setting proposal

The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...
Read More
The Senate’s latest price setting proposal will undermine U.S. economic growth

Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines, American medical innovation and our health care system as a whole. But there is another...
Read More
Celebrating Medicare’s 57th anniversary

In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans...
Read More
The Senate’s latest price setting proposal will undermine: Our health care system

Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...
Read More
New research shows competition driven by biosimilars helps control costs in Part B

Discussions about spending in Medicare Part B, including a recent report from the Medicare Payment Advisory Commission, or MedPAC, too often overlook how competition between medicines drives down the...
Read More
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients

As policymakers race to pass government price setting policies, it’s important to examine true public sentiment around such proposals. Voters have made clear that they do not support policies such as...
Read More